Obstructive sleep apnea-hypopnea syndrome and nonalcoholic fatty liver disease: Emerging evidence and mechanisms

Seminars in Liver Disease

Volumn 32, Issue 1, 2012, Pages 49-64

  Musso, Giovanni ^a   Olivetti, Carla ^a   Cassader, Maurizio ^b   Gambino, Roberto ^b  

^a GRADENIGO HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

chronic intermittent hypoxia; fatty liver; hypoxia inducible factor; Sleep apnea

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; HYPOXIA INDUCIBLE FACTOR 3ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LEPTIN; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; CLINICAL EXAMINATION; CLINICAL PROTOCOL; CLINICAL RESEARCH; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE SEVERITY; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; EVIDENCE BASED MEDICINE; HEPATIC ARTERY; HISTOPATHOLOGY; HUMAN; HYPOXIA; INSULIN RESISTANCE; LIVER; LIVER BIOPSY; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER INJURY; MEDIATOR; METABOLIC DISORDER; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXYGEN BLOOD LEVEL; PATHOGENESIS; PATHOPHYSIOLOGY; POLYSOMNOGRAPHY; POSITIVE END EXPIRATORY PRESSURE; PREVALENCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SLEEP APNEA SYNDROME; SYMPTOM; TONSILLECTOMY; UNFOLDED PROTEIN RESPONSE;

ADIPOSE TISSUE; ANIMALS; ANOXIA; FATTY LIVER; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; INFLAMMATION; NF-KAPPA B; SLEEP APNEA, OBSTRUCTIVE; UNFOLDED PROTEIN RESPONSE;

EID: 84857948775     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0032-1306426     Document Type: Review

References (134)

1. Younossi ZM, Stepanova M, Afendy M., et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol: 2011; 9 6 524 530, e1, quiz e60
2. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med: 2011; 43 8 617 649
3. Ghouri N, Preiss D, Sattar N. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology: 2010; 52 3 1156 1161
4. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med: 1993; 328 17 1230 1235 (Pubitemid 23115702)
5. Lindberg E, Gislason T. Epidemiology of sleep-related obstructive breathing. Sleep Med Rev: 2000; 4 5 411 433
6. West SD, Nicoll DJ, Stradling JR. Prevalence of obstructive sleep apnoea in men with type 2 diabetes. Thorax: 2006; 61 11 945 950 (Pubitemid 44787163)
7. Coughlin SR, Mawdsley L, Mugarza JA, Calverley PM, Wilding JP. Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur Heart J: 2004; 25 9 735 741 (Pubitemid 38647933)
8. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet: 2005; 365 9464 1046 1053 (Pubitemid 40386782)
9. Drager LF, Polotsky VY, Lorenzi-Filho G. Obstructive sleep apnea: an emerging risk factor for atherosclerosis. Chest: 2011; 140 2 534 542
10. Sharma SK, Agrawal S, Damodaran D., et al. CPAP for the metabolic syndrome in patients with obstructive sleep apnea. N Engl J Med: 2011; 365 24 2277 2286
11. Abe H, Takahashi M, Yaegashi H., et al. Efficacy of continuous positive airway pressure on arrhythmias in obstructive sleep apnea patients. Heart Vessels: 2010; 25 1 63 69
12. Drager LF, Bortolotto LA, Figueiredo AC, Krieger EM, Lorenzi GF. Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med: 2007; 176 7 706 712 (Pubitemid 47503079)
13. Shaw JE, Punjabi NM, Wilding JP, Alberti KG, Zimmet PZ.; International Diabetes Federation Taskforce on Epidemiology and Prevention. Sleep-disordered breathing and type 2 diabetes: a report from the International Diabetes Federation Taskforce on Epidemiology and Prevention. Diabetes Res Clin Pract: 2008; 81 1 2 12 (Pubitemid 351778429)
14. Iber C, Ancoli-Israel S, Chesson A., et al. The AASM manual for snoring of sleep and associated events: rules, terminology and technical specifications. 1st ed. Westchester, IL American Academy of Sleep Medicine: 2007
15. Dancey DR, Hanly PJ, Soong C, Lee B, Shepard J Jr, Hoffstein V. Gender differences in sleep apnea: the role of neck circumference. Chest: 2003; 123 5 1544 1550 (Pubitemid 36549774)
16. Strauss RS, Browner WS. Risk for obstructive sleep apnea. Ann Intern Med: 2000; 132 9 758 759
17. Rowley JA, Aboussouan LS, Badr MS. The use of clinical prediction formulas in the evaluation of obstructive sleep apnea. Sleep: 2000; 23 7 929 938
18. Mulgrew AT, Fox N, Ayas NT, Ryan CF. Diagnosis and initial management of obstructive sleep apnea without polysomnography: a randomized validation study. Ann Intern Med: 2007; 146 3 157 166 (Pubitemid 351650628)
19. Magalang UJ, Dmochowski J, Veeramachaneni S., et al. Prediction of the apnea-hypopnea index from overnight pulse oximetry. Chest: 2003; 124 5 1694 1701 (Pubitemid 37433561)
20. Cheliout-Heraut F, Senny F, Djouadi F, Ouayoun M, Bour F. Obstructive sleep apnoea syndrome: comparison between polysomnography and portable sleep monitoring based on jaw recordings. Neurophysiol Clin: 2011; 41 4 191 198
21. Jungermann K, Kietzmann T. Oxygen: modulator of metabolic zonation and disease of the liver. Hepatology: 2000; 31 2 255 260 (Pubitemid 30078586)
22. Fandrey J, Gassmann M. Oxygen sensing and the activation of the hypoxia inducible factor 1 (HIF-1)invited article. Adv Exp Med Biol: 2009; 648 197 206
23. Broughan TA, Naukam R, Tan C, Van De Wiele CJ, Refai H, Teague TK. Effects of hepatic zonal oxygen levels on hepatocyte stress responses. J Surg Res: 2008; 145 1 150 160
24. Baze MM, Schlauch K, Hayes JP. Gene expression of the liver in response to chronic hypoxia. Physiol Genomics: 2010; 41 275 288
25. Piguet AC, Stroka D, Zimmermann A, Dufour JF. Hypoxia aggravates non-alcoholic steatohepatitis in mice lacking hepatocellular PTEN. Clin Sci (Lond): 2010; 118 6 401 410
26. Reinke C, Bevans-Fonti S, Drager LF, Shin MK, Polotsky VY. Effects of different acute hypoxic regimens on tissue oxygen profiles and metabolic outcomes. J Appl Physiol: 2011; 111 3 881 890
27. Choi JH, Park MJ, Kim KW., et al. Molecular mechanism of hypoxia-mediated hepatic gluconeogenesis by transcriptional regulation. FEBS Lett: 2005; 579 13 2795 2801
28. Kietzmann T, Cornesse Y, Brechtel K, Modaressi S, Jungermann K. Perivenous expression of the mRNA of the three hypoxia-inducible factor alpha-subunits, HIF1alpha, HIF2alpha and HIF3alpha, in rat liver. Biochem J: 2001; 354 Pt 3 531 537 (Pubitemid 32269716)
29. Kenneth NS, Rocha S. Regulation of gene expression by hypoxia. Biochem J: 2008; 414 1 19 29
30. Dimova EY, Kietzmann T. Hypoxia-inducible factors: post-translational crosstalk of signaling pathways. Methods Mol Biol: 2010; 647 215 236
31. Jaakkola P, Mole DR, Tian YM., et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science: 2001; 292 5516 468 472 (Pubitemid 32335942)
32. Benita Y, Kikuchi H, Smith AD, Zhang MQ, Chung DC, Xavier RJ. An integrative genomics approach identifies hypoxia inducible factor-1 (HIF-1)-target genes that form the core response to hypoxia. Nucleic Acids Res: 2009; 37 14 4587 4602
33. Rankin EB, Rha J, Selak MA., et al. Hypoxia-inducible factor 2 regulates hepatic lipid metabolism. Mol Cell Biol: 2009; 29 16 4527 4538
34. Qu A, Taylor M, Xue X., et al. Hypoxia-inducible transcription factor 2 promotes steatohepatitis through augmenting lipid accumulation, inflammation, and fibrosis. Hepatology: 2011; 54 2 472 483
35. Nath B, Levin I, Csak T., et al. Hepatocyte-specific hypoxia-inducible factor-1 is a determinant of lipid accumulation and liver injury in alcohol-induced steatosis in mice. Hepatology: 2011; 53 5 1526 1537
36. Li J, Savransky V, Nanayakkara A, Smith PL, O'Donnell CP, Polotsky VY. Hyperlipidemia and lipid peroxidation are dependent on the severity of chronic intermittent hypoxia. J Appl Physiol: 2007; 102 2 557 563 (Pubitemid 46220883)
37. Drager LF, Li J, Shin MK., et al. Intermittent hypoxia inhibits clearance of triglyceride-rich lipoproteins and inactivates adipose lipoprotein lipase in a mouse model of sleep apnoea. Eur Heart J: 2011
38. Kucejova B, Sunny NE, Nguyen AD., et al. Uncoupling hypoxia signaling from oxygen sensing in the liver results in hypoketotic hypoglycemic death. Oncogene: 2011; 30 18 2147 2160
39. Marn-Hernndez A, Gallardo-Prez JC, Ralph SJ, Rodrguez-Enrquez S, Moreno-Snchez R. HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev Med Chem: 2009; 9 9 1084 1101
40. Copple BL, Bai S, Moon JO. Hypoxia-inducible factor-dependent production of profibrotic mediators by hypoxic Kupffer cells. Hepatol Res: 2010; 40 5 530 539
41. Moon JO, Welch TP, Gonzalez FJ, Copple BL. Reduced liver fibrosis in hypoxia-inducible factor-1alpha-deficient mice. Am J Physiol Gastrointest Liver Physiol: 2009; 296 3 G582 G592
42. Copple BL, Bai S, Burgoon LD, Moon JO. Hypoxia-inducible factor-1 regulates the expression of genes in hypoxic hepatic stellate cells important for collagen deposition and angiogenesis. Liver Int: 2011; 31 2 230 244
43. Shi YF, Fong CC, Zhang Q., et al. Hypoxia induces the activation of human hepatic stellate cells LX-2 through TGF-beta signaling pathway. FEBS Lett: 2007; 581 2 203 210 (Pubitemid 46096462)
44. Musso G, Gambino R, Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res: 2009; 48 1 1 26
45. Imtiyaz HZ, Williams EP, Hickey MM., et al. Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation. J Clin Invest: 2010; 120 8 2699 2714
46. Gambino R, Musso G, Cassader M. Redox balance in the pathogenesis of nonalcoholic fatty liver disease: mechanisms and therapeutic opportunities. Antioxid Redox Signal: 2011; 15 5 1325 1365
47. Coulon S, Heindryckx F, Geerts A, Van Steenkiste C, Colle I, Van Vlierberghe H. Angiogenesis in chronic liver disease and its complications. Liver Int: 2011; 31 2 146 162
48. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology: 2010; 51 5 1820 1832
49. Bangoura G, Liu ZS, Qian Q, Jiang CQ, Yang GF, Jing S. Prognostic significance of HIF-2alpha/EPAS1 expression in hepatocellular carcinoma. World J Gastroenterol: 2007; 13 23 3176 3182 (Pubitemid 47064579)
50. Dai CX, Gao Q, Qiu SJ., et al. Hypoxia-inducible factor-1 alpha, in association with inflammation, angiogenesis and MYC, is a critical prognostic factor in patients with HCC after surgery. BMC Cancer: 2009; 9 418
51. Daskalow K, Rohwer N, Raskopf E., et al. Role of hypoxia-inducible transcription factor 1alpha for progression and chemosensitivity of murine hepatocellular carcinoma. J Mol Med (Berl): 2010; 88 8 817 827
52. Sun X, Jiang H, Jiang X., et al. Antisense hypoxia-inducible factor-1alpha augments transcatheter arterial embolization in the treatment of hepatocellular carcinomas in rats. Hum Gene Ther: 2009; 20 4 314 324
53. Greenberger LM, Horak ID, Filpula D., et al. A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther: 2008; 7 11 3598 3608
54. Liu F, Wang P, Jiang X., et al. Antisense hypoxia-inducible factor 1alpha gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma. Cancer Sci: 2008; 99 10 2055 2061
55. Clment S, Juge-Aubry C, Sgroi A., et al. Monocyte chemoattractant protein-1 secreted by adipose tissue induces direct lipid accumulation in hepatocytes. Hepatology: 2008; 48 3 799 807
56. Alisi A, Panera N, Balsano C, Nobili V. Activation of the endotoxin/toll-like receptor 4 pathway: the way to go from nonalcoholic steatohepatitis up to hepatocellular carcinoma. Hepatology: 2011; 53 3 1069
57. Musso G, Gambino R, Cassader M. Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded? Diabetes Care: 2010; 33 10 2277 2284
58. Csak T, Ganz M, Pespisa J, Kodys K, Dolganiuc A, Szabo G. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology: 2011; 54 1 133 144
59. Musso G, Gambino R, Cassader M. Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes. Annu Rev Med: 2011; 62 361 380
60. Scharte M, Han X, Uchiyama T, Tawadrous Z, Delude RL, Fink MP. LPS increases hepatic HIF-1alpha protein and expression of the HIF-1-dependent gene aldolase A in rats. J Surg Res: 2006; 135 2 262 267 (Pubitemid 44414898)
61. Rius J, Guma M, Schachtrup C., et al. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature: 2008; 453 7196 807 811 (Pubitemid 351793778)
62. Mauro C, Leow SC, Anso E., et al. NF-B controls energy homeostasis and metabolic adaptation by upregulating mitochondrial respiration. Nat Cell Biol: 2011; 13 10 1272 1279
63. Ncher M, Farr R, Montserrat JM., et al. Biological consequences of oxygen desaturation and respiratory effort in an acute animal model of obstructive sleep apnea (OSA). Sleep Med: 2009; 10 8 892 897
64. Jelic S, Lederer DJ, Adams T., et al. Vascular inflammation in obesity and sleep apnea. Circulation: 2010; 121 8 1014 1021
65. Lam JC, Mak JC, Ip MS. Obesity, obstructive sleep apnea and metabolic syndrome. Respirology: 2012; 17 2 223 236
66. Beraza N, Malato Y, Vander Borght S., et al. Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis. Gut: 2008; 57 5 655 663 (Pubitemid 351579980)
67. Videla LA, Tapia G, Rodrigo R., et al. Liver NF-kappaB and AP-1 DNA binding in obese patients. Obesity (Silver Spring): 2009; 17 5 973 979
68. Luedde T, Schwabe RFNF. NF-B in the liverlinking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol: 2011; 8 2 108 118
69. He G, Karin MNF. NF-B and STAT3 - key players in liver inflammation and cancer. Cell Res: 2011; 21 1 159 168
70. Robinson SM, Mann DA. Role of nuclear factor kappaB in liver health and disease. Clin Sci (Lond): 2010; 118 12 691 705
71. Culver C, Sundqvist A, Mudie S, Melvin A, Xirodimas D, Rocha S. Mechanism of hypoxia-induced NF-kappaB. Mol Cell Biol: 2010; 30 20 4901 4921
72. Melvin A, Mudie S, Rocha S. Further insights into the mechanism of hypoxia-induced NFB. [corrected]. Cell Cycle: 2011; 10 6 879 882
73. Li J, Fan R, Zhao S., et al. Reactive oxygen species released from hypoxic hepatocytes regulates MMP-2 expression in hepatic stellate cells. Int J Mol Sci: 2011; 12 4 2434 2447
74. Snapp E. Endoplasmic reticulum biogenesis proliferation and differentiation. In: Mullins C., ed. The Biogenesis of Cellular Organelles. New York Kluwer Academic/Plenum: 2005; 63 95
75. Malhi H, Kaufman RJ. Endoplasmic reticulum stress in liver disease. J Hepatol: 2011; 54 4 795 809
76. Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science: 2011; 334 6059 1081 1086
77. Hetz C, Martinon F, Rodriguez D, Glimcher LH. The unfolded protein response: integrating stress signals through the stress sensor IRE1 Physiol Rev: 2011; 91 4 1219 1243
78. Diehl JA, Fuchs SY, Koumenis C. The cell biology of the unfolded protein response. Gastroenterology: 2011; 141 1 38 41, 41, e1-e2
79. Rahman SM, Schroeder-Gloeckler JM, Janssen RC., et al. CCAAT/enhancing binding protein beta deletion in mice attenuates inflammation, endoplasmic reticulum stress, and lipid accumulation in diet-induced nonalcoholic steatohepatitis. Hepatology: 2007; 45 5 1108 1117 (Pubitemid 46775772)
80. Kammoun HL, Chabanon H, Hainault I., et al. GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice. J Clin Invest: 2009; 119 5 1201 1215
81. Rinella ME, Siddiqui MS, Gardikiotes K, Gottstein J, Elias M, Green RM. Dysregulation of the unfolded protein response in db/db mice with diet-induced steatohepatitis. Hepatology: 2011; 54 5 1600 1609
82. Glimcher LH, Lee AH. From sugar to fat: How the transcription factor XBP1 regulates hepatic lipogenesis. Ann N Y Acad Sci: 2009; 1173 Suppl 1 E2 E9
83. Ning J, Hong T, Ward A., et al. Constitutive role for IRE1-XBP1 signaling pathway in the insulin-mediated hepatic lipogenic program. Endocrinology: 2011; 152 6 2247 2255
84. Gentile CL, Frye M, Pagliassotti MJ. Endoplasmic reticulum stress and the unfolded protein response in nonalcoholic fatty liver disease. Antioxid Redox Signal: 2011; 15 2 505 521
85. Gregor MF, Yang L, Fabbrini E., et al. Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss. Diabetes: 2009; 58 3 693 700
86. Puri P, Mirshahi F, Cheung O., et al. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology: 2008; 134 2 568 576 (Pubitemid 351173040)
87. Al-Rawashdeh FY, Scriven P, Cameron IC, Vergani PV, Wyld L. Unfolded protein response activation contributes to chemoresistance in hepatocellular carcinoma. Eur J Gastroenterol Hepatol: 2010; 22 9 1099 1105
88. Blais JD, Addison CL, Edge R., et al. Perk-dependent translational regulation promotes tumor cell adaptation and angiogenesis in response to hypoxic stress. Mol Cell Biol: 2006; 26 24 9517 9532 (Pubitemid 44904443)
89. van den Beucken T, Magagnin MG, Jutten B., et al. Translational control is a major contributor to hypoxia induced gene expression. Radiother Oncol: 2011; 99 3 379 384
90. Zhu Y, Fenik P, Zhan G, Sanfillipo-Cohn B, Naidoo N, Veasey SC. Eif-2a protects brainstem motoneurons in a murine model of sleep apnea. J Neurosci: 2008; 28 9 2168 2178 (Pubitemid 351317639)
91. Ip MS, Lam B, Ng MM, Lam WK, Tsang KW, Lam KS. Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med: 2002; 165 5 670 676 (Pubitemid 34194755)
92. Punjabi NM, Sorkin JD, Katzel LI, Goldberg AP, Schwartz AR, Smith PL. Sleep-disordered breathing and insulin resistance in middle-aged and overweight men. Am J Respir Crit Care Med: 2002; 165 5 677 682 (Pubitemid 34194756)
93. Makino S, Handa H, Suzukawa K., et al. Obstructive sleep apnoea syndrome, plasma adiponectin levels, and insulin resistance. Clin Endocrinol (Oxf): 2006; 64 1 12 19
94. Polotsky VY, Li J, Punjabi NM., et al. Intermittent hypoxia increases insulin resistance in genetically obese mice. J Physiol: 2003; 552 Pt 1 253 264 (Pubitemid 37265483)
95. Iiyori N, Alonso LC, Li J., et al. Intermittent hypoxia causes insulin resistance in lean mice independent of autonomic activity. Am J Respir Crit Care Med: 2007; 175 8 851 857 (Pubitemid 46631798)
96. Oltmanns KM, Gehring H, Rudolf S., et al. Hypoxia causes glucose intolerance in humans. Am J Respir Crit Care Med: 2004; 169 11 1231 1237 (Pubitemid 38680401)
97. Schahin SP, Nechanitzky T, Dittel C., et al. Long-term improvement of insulin sensitivity during CPAP therapy in the obstructive sleep apnoea syndrome. Med Sci Monit: 2008; 14 3 CR117 CR121 (Pubitemid 351457407)
98. Harsch IA, Schahin SP, Radespiel-Tröger M., et al. Continuous positive airway pressure treatment rapidly improves insulin sensitivity in patients with obstructive sleep apnea syndrome. Am J Respir Crit Care Med: 2004; 169 2 156 162 (Pubitemid 38114528)
99. Lam JC, Lam B, Yao TJ., et al. A randomised controlled trial of nasal continuous positive airway pressure on insulin sensitivity in obstructive sleep apnoea. Eur Respir J: 2010; 35 1 138 145
100. Musso G, Gambino R, Durazzo M., et al. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology: 2005; 42 5 1175 1183 (Pubitemid 43112685)
101. Musso G, Gambino R, Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes Rev: 2010; 11 6 430 445
102. Xu H, Barnes GT, Yang Q., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest: 2003; 112 12 1821 1830 (Pubitemid 38063705)
103. Makkonen J, Westerbacka J, Kolak M., et al. Increased expression of the macrophage markers and of 11beta-HSD-1 in subcutaneous adipose tissue, but not in cultured monocyte-derived macrophages, is associated with liver fat in human obesity. Int J Obes (Lond): 2007; 31 10 1617 1625 (Pubitemid 47482653)
104. Pasarica M, Sereda OR, Redman LM., et al. Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. Diabetes: 2009; 58 3 718 725
105. Wang B, Wood IS, Trayhurn P. Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes. Pflugers Arch: 2007; 455 3 479 492 (Pubitemid 47624196)
106. Ye J, Gao Z, Yin J, He Q. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endocrinol Metab: 2007; 293 4 E1118 E1128 (Pubitemid 47535846)
107. Yin J, Gao Z, He Q, Zhou D, Guo Z, Ye J. Role of hypoxia in obesity-induced disorders of glucose and lipid metabolism in adipose tissue. Am J Physiol Endocrinol Metab: 2009; 296 2 E333 E342
108. Nakagawa Y, Kishida K, Kihara S, Yoshida R, Funahashi T, Shimomura I. Nocturnal falls of adiponectin levels in sleep apnea with abdominal obesity and impact of hypoxia-induced dysregulated adiponectin production in obese murine mesenteric adipose tissue. J Atheroscler Thromb: 2011; 18 3 240 247
109. Nakagawa Y, Kishida K, Kihara S., et al. Nocturnal reduction in circulating adiponectin concentrations related to hypoxic stress in severe obstructive sleep apnea-hypopnea syndrome. Am J Physiol Endocrinol Metab: 2008; 294 4 E778 E784 (Pubitemid 351483603)
110. Tann F, Gagnadoux F, Chazouillres O., et al. Chronic liver injury during obstructive sleep apnea. Hepatology: 2005; 41 6 1290 1296 (Pubitemid 40770281)
111. Singh H, Pollock R, Uhanova J, Kryger M, Hawkins K, Minuk GY. Symptoms of obstructive sleep apnea in patients with nonalcoholic fatty liver disease. Dig Dis Sci: 2005; 50 12 2338 2343 (Pubitemid 43106390)
112. Tatsumi K, Saibara T. Effects of obstructive sleep apnea syndrome on hepatic steatosis and nonalcoholic steatohepatitis. Hepatol Res: 2005; 33 2 100 104 (Pubitemid 41799784)
113. Kallwitz ER, Herdegen J, Madura J, Jakate S, Cotler SJ. Liver enzymes and histology in obese patients with obstructive sleep apnea. J Clin Gastroenterol: 2007; 41 10 918 921 (Pubitemid 350307079)
114. Jout P, Sabat JM, Maillard D., et al. Relationship between obstructive sleep apnea and liver abnormalities in morbidly obese patients: a prospective study. Obes Surg: 2007; 17 4 478 485 (Pubitemid 46850187)
115. Mishra P, Nugent C, Afendy A., et al. Apnoeic-hypopnoeic episodes during obstructive sleep apnoea are associated with histological nonalcoholic steatohepatitis. Liver Int: 2008; 28 8 1080 1086
116. Campos GM, Bambha K, Vittinghoff E., et al. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology: 2008; 47 6 1916 1923 (Pubitemid 351945559)
117. Norman D, Bardwell WA, Arosemena F., et al. Serum aminotransferase levels are associated with markers of hypoxia in patients with obstructive sleep apnea. Sleep: 2008; 31 1 121 126
118. Polotsky VY, Patil SP, Savransky V., et al. Obstructive sleep apnea, insulin resistance, and steatohepatitis in severe obesity. Am J Respir Crit Care Med: 2009; 179 3 228 234
119. Daltro C, Cotrim HP, Alves E., et al. Nonalcoholic fatty liver disease associated with obstructive sleep apnea: just a coincidence? Obes Surg: 2010; 20 11 1536 1543
120. Turkay C, Ozol D, Kasapoglu B., et al. Influence of obstructive sleep apnea on fatty liver disease: role of chronic intermittent hypoxia. Respir Care: 2012; 57 2 244 249
121. Aron-Wisnewsky J, Minville C, Tordjman J., et al. Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. J Hepatol: 2012; 56 1 225 233
122. Chin K, Nakamura T, Takahashi K., et al. Effects of obstructive sleep apnea syndrome on serum aminotransferase levels in obese patients. Am J Med: 2003; 114 5 370 376 (Pubitemid 36513685)
123. Kheirandish-Gozal L, Sans Capdevila O, Kheirandish E, Gozal D. Elevated serum aminotransferase levels in children at risk for obstructive sleep apnea. Chest: 2008; 133 1 92 99
124. Shpirer I, Copel L, Broide E, Elizur A. Continuous positive airway pressure improves sleep apnea associated fatty liver. Lung: 2010; 188 4 301 307
125. Kohler M, Pepperell JC, Davies RJ, Stradling JR. Continuous positive airway pressure and liver enzymes in obstructive sleep apnoea: data from a randomized controlled trial. Respiration: 2009; 78 2 141 146
126. Savransky V, Nanayakkara A, Vivero A., et al. Chronic intermittent hypoxia predisposes to liver injury. Hepatology: 2007; 45 4 1007 1013 (Pubitemid 46631569)
127. Li J, Grigoryev DN, Ye SQ., et al. Chronic intermittent hypoxia upregulates genes of lipid biosynthesis in obese mice. J Appl Physiol: 2005; 99 5 1643 1648 (Pubitemid 41547158)
128. Savransky V, Bevans S, Nanayakkara A., et al. Chronic intermittent hypoxia causes hepatitis in a mouse model of diet-induced fatty liver. Am J Physiol Gastrointest Liver Physiol: 2007; 293 4 G871 G877 (Pubitemid 47605939)
129. Drager LF, Li J, Reinke C, Bevans-Fonti S, Jun JC, Polotsky VY. Intermittent hypoxia exacerbates metabolic effects of diet-induced obesity. Obesity (Silver Spring): 2011; 19 11 2167 2174
130. Feng SZ, Tian JL, Zhang Q., et al. An experimental research on chronic intermittent hypoxia leading to liver injury. Sleep Breath: 2011; 15 3 493 502
131. Musso G, Gambino R, Cassader M. Need for a three-focused approach to nonalcoholic fatty liver disease. Hepatology: 2011; 53 5 1773, author reply 1774
132. Harsch IA, Schahin SP, Brückner K., et al. The effect of continuous positive airway pressure treatment on insulin sensitivity in patients with obstructive sleep apnoea syndrome and type 2 diabetes. Respiration: 2004; 71 3 252 259 (Pubitemid 38608343)
133. Coughlin SR, Mawdsley L, Mugarza JA, Wilding JP, Calverley PM. Cardiovascular and metabolic effects of CPAP in obese males with OSA. Eur Respir J: 2007; 29 4 720 727 (Pubitemid 46554622)
134. Vgontzas AN, Bixler EO, Chrousos GP. Sleep apnea is a manifestation of the metabolic syndrome. Sleep Med Rev: 2005; 9 3 211 224 (Pubitemid 40694188)